Emeryville, CA, United States of America

Glenn C Michelson



Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Glenn C Michelson: Innovator in Cancer Treatment

Introduction

Glenn C Michelson is a notable inventor based in Emeryville, CA (US). He has made significant contributions to the field of cancer treatment, particularly in addressing drug-resistant forms of the disease. His innovative approach has the potential to improve the lives of many patients facing this challenging condition.

Latest Patents

Michelson holds a patent for "Methods for treating drug resistant cancer." This patent describes a method for treating drug-resistant cancer by administering a compound of formula I, or its variants, to patients in need. The method specifically targets cancer patients who are resistant to conventional drug treatments, offering a new avenue for therapeutic intervention.

Career Highlights

Glenn C Michelson is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on groundbreaking research and development in the pharmaceutical sector. With a patent portfolio that includes 1 patent, Michelson continues to push the boundaries of medical science.

Collaborations

Throughout his career, Michelson has collaborated with talented professionals in the field, including Vivien W Chan and Carla C Heise. These collaborations have fostered an environment of innovation and have contributed to the advancement of cancer treatment methodologies.

Conclusion

Glenn C Michelson's contributions to cancer treatment exemplify the impact of innovative thinking in medicine. His work not only highlights the importance of addressing drug resistance in cancer therapy but also showcases the collaborative spirit of research and development in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…